Management of HIV and hepatitis virus coinfection

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 15, 2010, Pages 2497-2516

  Mendes Corra, Mariacssia ^a   Nez, Marina ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

HAART; HIVHBV coinfection; HIVHCV coinfection; Nucleos(t)ide analogues; Pegylated interferon alpha

Indexed keywords

ABACAVIR; ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEMOGLOBIN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; TELBIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADVERSE OUTCOME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DEPRESSION; DISEASE COURSE; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; FANCONI RENOTUBULAR SYNDROME; FLU LIKE SYNDROME; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL DISEASE; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; NON INVASIVE PROCEDURE; PATIENT SELECTION; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUBULAR DYSFUNCTION; VIRUS MUTATION; VIRUS REPLICATION; WEIGHT REDUCTION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE MANAGEMENT; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 77957069082     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.500615     Document Type: Review

References (194)

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745
2. Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002;360:1921-1926
3. Zhou J, Dore GJ, Zhang F, et al. Hepatitis B and C virus coinfection in the TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510-1518
4. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002
5. Krogsgaard K, Lindhart B, Nielsen J, et al. The influence of HTLV III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 1987;7:37-41
6. Bodsworth N, Donovan B, Nightingale B. The effects of concurrent HIV infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-582
7. Colin J, Cazals-Hatem D, Loriot A, et al. Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310
8. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-1058 (Pubitemid 29458296)
9. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926
10. Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006;44:S28-34
11. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-1641
12. Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4
13. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-497
14. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-217
15. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17:1803-1809
16. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-188
17. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009;23:1881-1889
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human services. 1st December 2009. p. 1-161. Available from: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. [Accessed 14th April 2010]
19. European AIDS Clinical Society. Guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults (version 5). Available from: http://www.europeanaidsclinicalsociety. org/guidelinespdf/3-Chronic-Hepatitis-B-&-C.pdf. [Accessed 14th April 2010]
20. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008;22:1399-1410
21. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-1035
22. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-148
23. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update Hepatology 2009;50:1-36
24. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13:627-631
25. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106:1000-1005
26. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007;21(6):771-774
27. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686
28. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
29. Di Martino V, Lunel F, Cadranel J, et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996;3:253-260
30. Di Martino V, Thevenot T, Boyer N, et al. Serum alanine transaminase level is a good predictor of response to interferon therapy for chronic hepatitis B in HIV-infected patients. Hepatology 2000;31:1030-1031
31. Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-1822 (Pubitemid 35408305)
32. Wursthorn K, Buggisch P, Lutgehetmann M, et al. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 2006;11(5):647-652
33. Johnson RM, Ristig MB, Overton ET, et al. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007;8:173-181
34. Weltman M, Brotodiharjo A, Crewe E, et al. Co-infection with chronic hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45
35. Dore J, Cooper D, Barret C, et al. Dual efficacy of lamivudine treatment of human immunodeficiency virus-hepatitis B coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180:607-613
36. Hoff J, Bani-Sadr F, Gassin M, et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-969
37. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999;30:1302-1306
38. Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus mutations associated with resistance to lamivudine in patients co-infected with HBV and HIV. J Clin Microbiol 1999;37:3013-3016
39. Pillay D, Cane P, Ratcliffe D, et al. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. AIDS 2000;14:1111-1116
40. Dienstag J, Goldin R, Heathcote E, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
41. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
42. Puoti M, Cozzi-Lepri A, Arici C, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HbsAg- and HIV-positive individuals: results from an intercohort analysis. Antivir Ther 2006;11:567-574
43. Rey D, Fritsch S, Schmitt C, et al. Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in HIV co-infected patients. Gastroenterol Clin Biol 2000;24:125-127
44. Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain is a cause of liver failure in an HIV-infected patient. Gastroenterology 2001;121:1027-1028
45. Proia L, Ngui S, Kaur S, et al. Reactivation of hepatitis B in patients with HIV infection treated with combination antiretroviral therapy. Am J Med 2000;108:249-251
46. Neau D, Schvoerer E, Robert D, et al. Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a HIV-infected patient. J Infect 2000;41:192-194
47. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-1116
48. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 Years. Gastroenterology 2006;131(6):1743-1751
49. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48(3):750-758
50. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-723
51. Pessoa MG, Gazzard B, Huang AK, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-1787
52. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507
53. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430
54. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001-1010
55. Sasadeusz J, Audsley JA, Mijch A, et al. The anti-HIV activity of entecavir: a multicenter evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008;22:947-955
56. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 2007;356(25):2614-2621
57. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357(25):2576-2588
58. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136(2):486-495
59. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009;23:546-547
60. Lin K, Karwowska S, Lam E, et al. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. J Antimicrob Agents Chemother 2010;54:2670-2673
61. Ying C, De Clercq E, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000;7:161-165
62. Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-508
63. Nunez M, Perez-Olmeda M, Diaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002;16:2352-2354
64. Ristig M, Crippin J, Aberg J, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-1847
65. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-10
66. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-178 (Pubitemid 36056731)
67. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455
68. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006;43(3):548-555
69. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and - experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189(7):1185-1192
70. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2(3):266-272
71. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
72. Snow-Lampart A, Chappell BJ, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd. Hepatology 2008;48(Suppl):745A
73. Verhelts D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-1333
74. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004;18:1074-1076
75. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-1198
76. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166(1):49-56
77. Papatheodoridis G, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-1628
78. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075
79. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194
80. Degertekin B, Lok AS. Indications for treatment in Hepatitis B. Hepatology 2009;49(5 Suppl):S129-37
81. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009;23(15):1971-1975
82. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42(2):283-290
83. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006;43(3):278-283
84. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83(2):265-272
85. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197(1):102-108
86. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S122-8
87. Peters MG, Hann H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126(1):91-101 (Pubitemid 38040727)
88. Matthews GV, Avihingsanon A, lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/ HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008;48:1062-1069
89. van Bommel F, de Man RA, Wedemeyer H. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
90. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1355-1374
91. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-657
92. Lissen E, Clumeck N, Sola R, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirinin HIV-hepatitis C virus co-infection. AIDS 2006;20:2175-2181
93. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007;46:613-619
94. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007;38:32-38
95. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008;23:1000-1008
96. Shores NJ, Maida I, Soriano V, Nunez M. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol 2008;49:323-328
97. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-1089
98. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350
99. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41(1):48-54
100. Sterling RK, Lissen E, Clumeck N. Development of a simple noninvasive index to predict significantfibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325
101. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005;6:375-378
102. Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84
103. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003;17:721-725
104. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008;47:94-101
105. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21:2209-2216
106. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450
107. Nunez M, Ocampo A, Aguirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/ HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008;15:363-369
108. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/ HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-5
109. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459
110. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848
111. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36
112. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-238
113. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy forchronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023-1028 (Pubitemid 36549714)
114. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentreitalian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfectedpatients on HAART. Antivir Ther 2005;10:309-317
115. Santin M, Shaw E, Garcia MJ, et al. Efficacy and safety of pegylated interferon-alpha2b plusribavirin for the treatment of chronic hepatitis C in HIV infected patients. AIDS Res Hum Retroviruses 2006;22:315-320
116. Voigt E, Schulz C, Klausen G, et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV coinfected patients. J Infect 2006;53:36-42
117. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-982
118. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49:22-31
119. Gluud LL, Marchesini E, Iorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. Am J Gastroenterol 2009;104:2335-2341
120. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007;14:239-248
121. Hadziyannis SJ, Vassilopoulos D. Complex management issues: management of HCV in the atypical patient. Baillieres Best Pract Res Clin Gastroenterol 2000;14:277-291
122. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
123. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
124. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355
125. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005;39(4):401-405
126. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or N Engl J Med 2005;352:2609-2617
127. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097
128. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-460
129. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ ribavirin therapy. Hepatology 2006;43:954-960
130. Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 2007;21:477-481
131. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006;7:248-254
132. Van den Eynde E, Crespo M, Esteban JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009;48:1152-1159
133. Pariante CM, Orru MG, Baita A, et al. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354(9173):131-132
134. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344(13):961-966
135. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-451
136. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42(6):793-798
137. Cai W, Khaoustov VI, Xie Q, et al. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005;42:880-887
138. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-1379
139. Nunez M, Ocampo A, Aguirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/ HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008;15:363-369
140. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-437 (Pubitemid 352016736)
141. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analoguebackbone. J Antimicrob Chemother 2008;62:1365-1373
142. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination:does abacavir play a role? J Acquir Immune Defic Syndr 2007;45:123-125
143. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008;13:953-957
144. Dieterich DT, Rizzetto M, Manns MP. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. J Viral Hepat 2009;16:833-843
145. Myers RP, Benhamou Y, Bochet M, et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004;18:75-79
146. Crespo M, Mira A, Pineda J, et al. Efficacy of peguilated interferon ans ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon based regimen. J Antimicrob Chemother 2008;62:793-796
147. Bruix J, Poynard T, Colombo M, et al. PegIntron maintenance therapy in cirrhotic (Metavir F4) HCV patients who failed to respond to interferon/ribavirin (IR) therapy: final Results of the EPIC3 Cirrhosis Maintenance Trial. 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, 22 - 26 April 2009.
148. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441
149. Sherman K, Andersen J, Butt A, et al. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV-co-infected patients: early viral response and effect on fibrosis in treated and control subjects [abstract 59]. 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, 3 - 6 February 2008.
150. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009;23:F1-7
151. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother 2010;65:4-9
152. Dionne-Odom J, Osborn MK, Radziewicz H, et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis 2009;9:775-783
153. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010;138:123-135
154. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009;18:709-725
155. Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-159
156. McHutchison JG, Manns MP, Muir A, et al. PROVE 3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy [abstract 66]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, October 30 - November 1 2009
157. Marcellin P, Forns X, Goeser T, et al. Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208 [abstract 194]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, October 30 - November 1 2009
158. Kwo PY, Lawitz E, McCone J, et al. High Sustained Virologic Response (SVR) in Genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with Boceprevir (Boc) combination therapy [abstract 62]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, October 30 - November 1 2009
159. Sherman KE, Soriano V, Chung RT. Human immunodeficiency virus and liver disease: Conference Proceedings. Hepatology 2010;51:1046-1054
160. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777
161. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-1085
162. Kempf D, Klein C, Chen H-J, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18:163-167
163. He Y, King MS, Kempf DJ, et al. Relative replication capacity and selective advantage profiles of protease inhibitorresistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 2008;52:1101-1110
164. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009;49:1069-1082
165. Lopez-Labrador FX, Moya A, Gonzales-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 2008;13:481-494
166. Morsica G, Bagaglio S, Uberti-Foppa C, et al. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009;51:106-108
167. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
168. Nattermann J, Vogel M, Baumgarten A, et al. Genetic variation in IL28B and treatment-induced clearance of HCV in HCV/HIV co-infected patients [abstract 164 LB]. 17th Conference on Retrovirus and Opportunistic Infections (CROI). San Francisco, 16 - 19 February 2010.
169. Rallon N, Naggie S, Benito J, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-9
170. Veronese L, Rautaureau J, Sadler BM, et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000;44:821-826
171. Meynard JL, Lacombe K, Poirier JM, et al. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. Antimicrob Chemother 2009;63:579-584
172. Miro JM, Aguero F, Laguno M, et al. Liver transplantation in HIV/hepatitis coinfection. J HIV Ther 2007;12:24-35
173. de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006;6:2983-2993
174. Di Benedetto F, Di Sandro S, De Ruvo N, et al. Human immunodeficiency virus and liver transplantation: our point of view. Transplant Proc 2008;40:1965-1971
175. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47:407-417
176. Testillano M, Fernandez JR, Suarez MJ, et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. Transplant Proc 2009;41:1041-1043
177. Schreibman I, Gaynor JJ, Jayaweera D, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007;84:697-705
178. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8:355-365
179. Duclos-Vallee JC, Feray C, Sebagh M, et al. Liver transplantation in HIV-HCV and HIVHBV coinfected patients: a large experience in a single centre. J Hepatol 2006;44:S8
180. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004;10:1271-1278
181. Fung J, Eghtesad B, Patel-Tom K, et al. Liver transplantation in patients with HIV infection. Liver Transpl 2004;10:S39-53
182. Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009;23(9):1069-1076
183. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010;16:56-63
184. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004;18(15):2039-2045
185. Puoti M, Cozzi-Lepri A, Ancarani F, et al. The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? Antivir Ther 2004;9(5):811-817
186. Lacombe K, Boyd A, Guechot J, et al. The long-term use of tenofovir in HIV/ HBV co-infection induces a marked decrease in liver fibrosis [abstract 815]. 16th Conference on Retrovirus and Opportunistic Infections, Montreal, Canada, 8 - 11th February 2009
187. Lee T, Nunez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009;10:153-159
188. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601
189. Bani-Sadr F, Bedossa P, Rosenthal E, et al. Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients? J Acquir Immune Defic Syndr 2009;50:234-236
190. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005;41:123-131
191. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713
192. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004;18:2163-2170
193. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55
194. Beltz A, High K, Nunez M. Effect of HIV on levels of serum markers of liver inflammation and fibrosis in hepatitis C virus co-infection [abstract 1343]. 60th Annual Meeting of the American Association for the Study of Liver Disease. Boston, MA, October 30th - November 3rd 2009